Peptide therapeutics for treating ocular surface infections

Journal of Ocular Pharmacology and Therapeutics

Volumn 30, Issue 9, 2014, Pages 691-699

  Brandt, Curtis R ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; PEPTIDE;

AMINO ACID SEQUENCE; ANTIBIOTIC THERAPY; BACTERIAL COUNT; DRUG EFFICACY; EYE INFECTION; EYE PROTECTION; HUMAN; KERATITIS; NONHUMAN; OCULAR SURFACE DISEASE; OUTCOME ASSESSMENT; PROTEIN DEGRADATION; REVIEW; TREATMENT RESPONSE; ANIMAL; ANTIBIOTIC RESISTANCE; DISEASE MODEL; DRUG DESIGN; DRUG POTENTIATION; MICROBIOLOGY;

ANIMALS; ANTI-INFECTIVE AGENTS; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUG RESISTANCE, MICROBIAL; DRUG SYNERGISM; HUMANS; KERATITIS; PEPTIDES;

EID: 84928555020     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2014.0089     Document Type: Review

References (73)

1. Wilhelmus, K.R. Review of clinical experience with mi-crobial keratitis associated with contact lenses. CLAO J. 13:211-214, 1987.
2. Liesegang, T.J. Epidemiology of ocular herpes simplex: natural history in Rochester, Minn. 1950 through 1982. Arch. Ophthalmol. 107:1160-1165, 1989.
3. Gonzalez-Lopez, J.J, Morcillo-Laiz, R., and Munoz-Ne-grete, F.J. Adenoviral keratoconjunctivitis: an update. Arch. Soc. Esp. Oftalmol. 88:108-115, 2013.
4. Pepose, J.S., Margolis, T.P., LaRussa, P., and Pavan-Langston, D. Ocular complications of smallpox vaccination. Am. J. Ophthalmol. 136:343-352, 2003.
5. McCulley, J.P, Alizadeh, H., and Niederkorn, J.Y. Acan-thamoeba keratitis. CLAO J. 21:73-76, 1995.
6. Pereira, H.A. Novel therapies based on cationic antimicrobial peptides. Curr. Pharm. Biotechnol. 7:229-234, 2006.
7. Silva, N.C., Sarmento, B., and Pintado, M. The importance of antimicrobial peptides and their potential for therapeutic use in ophthalmology. Int. J. Antmicrob. Agents 41:5-10, 2013.
8. Kolar, S.S., and McDermott, A.M. Role of host-defence peptides in eye diseases. Cell Mol. Life Sci. 68:2201-2213, 2011.
9. McDermott, A.M. Antimicrobial compounds in tears. Exp. Eye Res. 117:53-61, 2013.
10. Pearlman, E., Sun, Y., Roy, S., et al. Host defense at the ocular surface. Int. Rev. Immunol. 32:4-18, 2013.
11. McDermott, A.M., Rich, D., Cullor, J., et al. The in vitro activity of selected defensins against an isolate of Pseu-domonas in the presence of human tears. Br. J. Ophthalmol. 90:609-611, 2006.
12. Otri, M., Mohammed, I., Abedin, A., et al. Antimicrobial peptides expression by ocular surface cells in response to Acanthamoeba castellanii: an in vitro study. Br. J. Oph-thalmol. 94:1523-1527, 2010.
13. Mohammed, I., Abedin, A., Tsintzas, K., et al. Increased expression of hepcidin and toll-like receptors 8 and 10 in viral keratitis. Cornea. 30:899-904, 2011.
14. Gottsch, J.D., Li, Q., Ashraf, M.F., et al. Defensin gene expression in the cornea. Curr. Eye Res. 17:1082-1086, 1998.
15. Wu, M., McClellan, S.A., Barrett, R.P., and Hazlett, L.D. b-defensin-2 promotes resistance against infection with P. aeruginosa. J. Immunol. 182:1609-1616, 2009.
16. Augustin, D. K., Heimer, S.R., Tam, C., et al. Role of defensins in corneal epithelial barrier function against Pseudomonas aeruginosa traversal. Infect. Immun. 79:595-605, 2011.
17. Huang, L.C., Reins, R.Y., Gallo, R.L., and McDermott, A.M. Cathelicicin-deficient (Cnlp-/-) mice show increased susceptibility to Pseudomonas aeruginosa keratitis. Invest. Ophthalmol. Vis. Sci. 48:4498-4508, 2007.
18. Wu, M., McClellan, S.A., Barrett, R.P., Zhang, Y., and Hazlett, L.D. b-defensins 2 and 3 together promote resistance to Pseudomonas aeruginosa keratitis. J. Immunol. 183:8054-8060, 2009.
19. Kolar, S.S., Baidouri, H., Hanlon, S., and McDermott, A.M. Protective role of murine b-defensins 3 and 4 and cathelin-related antimicrobial peptide in Fusarium solani keratitis. Infect. Immun. 81:2669-2677, 2013.
20. Mannis, M.J. The use of antimicrobial peptides in ophthalmology: an experimental study in corneal preservation and the management of bacterial keratitis. Trans. Am. Ophthalmol. Soc. 99:243-271, 2001.
21. Bulet, P., Stocklin, R., and Menin, L. Antimicrobial pep-tides: from invertebrates to vertebrates. Immunol. Rev. 198:169-184, 2004.
22. Li, S.-A., Liu, J., Xiang, Y., et al. Therapeutic potential of the antimicrobial peptide OH-CATH30 for antibiotic-resistant Pseudomonas aeruginosa keratitis. Antimicrob. Agents Chemother. 58:3144-3150, 2014.
23. Nguyen, T.X., Cole, A.M., and Lehrer, R.I. Evolution of primate theta-defensins: a serpentine path to a sweet tooth. Peptides. 24:1647-1654, 2002.
24. Cole, A.M., Hong, T., Boo, L.M., et al. Retrocyclin: a primate peptide that protects cells from infection by T-and M-tropic strains of HIV-1. Proc. Natl. Acad. Sci. U. S. A. 99:1813-1818, 2002.
25. Leikina, E., Delanoe-Ayari, H., Melikov, K., et al. Carbohydrate-binding molecules inhibit viral fusion and entry by cross-linking membrane glycoproteins. Nat. Immunol. 6:995-1001, 2005.
26. Yasin, B., Wang, W., Pang, M., et al. Theta defensins protect cells from infection by herpes simplex virus by inhibiting viral adhesion and entry. J. Virol. 78:5147-5156, 2004.
27. Brandt, C.R., Akkarawongsa, R., Altmann, S., et al. Evaluation of a y-defensin in a murine model of herpes simplex virus type 1 keratitis. Invest. Ophthalmol. Vis. Sci. 48:5118-5124, 2007.
28. Brandt, C.R., Coakley, L.M., and Grau, D.R. A murine model of herpes simplex virus-induced ocular disease for antiviral drug testing. J. Virol. Methods. 36:209-222, 1992.
29. Pasupuleti, M., Chalupka, A., Morgelin, M., Schmidtchen, A., and Malmsten, M. Tryptophan end-tagging of antimicrobial peptides for increased potency against Pseudomo-nas aeruginosa. Biochim. Biophys. Acta. 1790:800-808, 2009.
30. Nos-Barbera, S., Portoles, M., Morilla, A., et al. Effect of hybrid peptides of cecropiin A and melittin in an experimental model of bacterial keratitis. Cornea. 16:101-106, 1997.
31. Bultmann, H., Teuton, J., and Brandt, C.R. Addition of a C-terminal cysteine improves the anti-herpes simplex virus activity of a peptide containing the human immunodeficiency virus type 1 tat protein transduction domain. Anti-microb. Agents Chemother. 51:1596-1607, 2007.
32. Tiwari, V., Liu, J., Valyi-Nagy, T., and Shukla, D. Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo. J. Biol. Chem. 286:25406-25415, 2011.
33. Sarac, M.S., Cameron, A., and Lindberg, I. The furin inhibitor hexa-D-arginine blocks the activation of Pseudo-monas aeruginosa exotoxin A in vivo. Infect. Immun. 70:7136-7139, 2002.
34. Hazlett, L.D., Berk, R.S., and Iglewski, B. H. Microscopic characterization of ocular damage produced by Pseudo-monas aeruginosa toxin A. Infect. Immun. 34:1025-1035, 1981.
35. Miyazaki, S., Matsumoto, T., Ohno, A., and Yamaguchi, K. Role of exotoxin A in inducing severe Pseudomonas aer-uginosa infections in mice. J. Med. Microbiol. 43:169-175, 1995.
36. Inocencio, N.M., Moehring, J.M., and Moehring, T.J. Furin activates Pseudomonas exotoxin A by specific cleavage in vivo and in vitro. J. Biol. Chem. 269:31831-31835, 1994.
37. Pillar, C.M., and Hobden, J.A. Pseudomonas aeruginosa exotoxin A and keratitis in mice. Invest. Ophthalmol. Vis. Sci. 43:1437-1444, 2002.
38. Karicherla, P., and Hobden, J.A. Nona-D-arginine therapy for Pseudomonas aeruginosa keratitis. Invest. Ophthalmol. Vis. Sci. 50:256-262, 2009.
39. Karicherla, P., Aras, S., Aiyar, A., and Hobden, J.A. Nona-D-arginine amide (D9R) suppresses corneal cytokines in Pseudomonas aeruginosa keratitis. Cornea. 29:1308-1314, 2010.
40. Zhao, G., Li, S., Zhao, W., et al. Phage display against corneal epithelial cells produced bioactive peptides that inhibit Aspergillus adhesion to the corneas. PLoS One. 7:e33578, 2012.
41. Dutia, B., Frame, M.C., Subak-Sharpe, J.H., Clark, W.N., and Marsden, H.S. Specific inhibition of herpes virus ri-bonucleotide reductase by synthetic peptides. Nature. 321:439-441, 1986.
42. Cohen, E.A., Gandreau, P., Brazeau, P., and Langelier, Y. Specific inhibition of herpes virus ribonucleotide reductase by a nonapeptide derived from the carboxy terminus of subunit 2. Nature. 321:441-443, 1986.
43. Bultmann, H., Busse, J.S., and Brandt, C.R. Modified FGF4 signal peptide inhibits entry of herpes simplex virus type 1. J. Virol. 75:2634-2645, 2001.
44. Bultmann, H., and Brandt, C.R. Peptides containing membrane-transiting motifs inhibit viral entry. J. Biol. Chem. 277:36018-36023, 2002.
45. Larsen, I.V., and Brandt, C.R. A cationic tat peptide inhibits herpes simplex virus infection of human corneal epithelial cells. J. Ocul. Pharmacol. Ther. 26:541-547, 2010.
46. Jose, G.G., Larsen, I.V., Gauger, J., et al. A cationic pep-tide, TAT-Cdo, inhibitis herpes simplex virus type 1 ocular infection in vivo. Invest. Ophthalmol. Vis. Sci. 54:1070-1079, 2013.
47. Akkarawongsa, R., Cullinan, A.E., Zinkel, A., Clarin, J., and Brandt, C.R. Corneal toxicity of cell-penetrating pep-tides that inhibit herpes simplex virus entry. J. Ocul. Pharmacol. Ther. 22:279-289, 2006.
48. Uchio, E., Inoue, H., and Kadonosono, K. Anti-adenoviral effects of human cationic antimicrobial protein-18/LL37, an antimicrobial peptide, by quantitative polymerase chain reaction. Korean J. Ophthalmol. 27:199-203, 2013.
49. Lee, C.-J., Buznyk, O., Kuffova, L., et al. Cathelicidin LL-37 and HSV-1 corneal infection: peptide versus gene therapy. Trans. Vis. Sci. Technol. 3:4, 2014.
50. Lin, W.R., Graham, J., MacGowan, S.M., Wilcock, G.K., and Itzhaki, R. Alzheimer's disease, herpes virus in brain, apolipoprotein E4 and herpes labialis. Alzheimers Rep. 1:173-178, 1998.
51. Hill, J.M., Battacharjee, P.S., and Neumann, D.M. Apoli-poprotein E alleles can contribute to the pathogenesis of numerous clinical conditions including HSV-1 corneal disease. Exp. Eye Res. 84:801-811, 2007.
52. Bhattacharjee, P.S., Neumann, D.M., Foster, T.P., et al. Effect of human apolipoprotein E genotype on the patho-genesis of experimental ocular HSV-1. Exp. Eye Res. 87:122-130, 2008.
53. Dobson, C.B., Sales, S.D., Hoggard, P., Wozniak, M.A., and Crutcher, K.A. The receptor-binding region of human apolipoprotein E has direct anti-infective activity. J. Infect. Dis. 193:442-450, 2006.
54. Battacharjee, P.S., Neumann, D.M., Foster, T.P., et al. Effective treatment of ocular HSK with a human apolipo-protein E mimetic peptide in a mouse eye model. Invest. Ophthalmol. Vis. Sci. 49:4263-4268, 2008.
55. Battacharjee, P.S., Neumann, D.M., and Hill, J.M. A human apolipoprotein E mimetic peptide effectively inhibits HSV-1 TK-positive and TK-negative acute epithelial ker-atitis in rabbits. Curr. Eye Res. 34:99-102, 2009.
56. Pereira, H.A., Erdem, I., Pohl, J., and Spitznagel, J.K. Synthetic bactericidal peptide based on CAP37: a 37kDA human neutrophil granule-associated cationic antimicrobial protein chemotactic for monocytes. Proc. Natl. Acad. Sci. U. S. A. 65:2803-2811, 1993.
57. Gordon, Y.J., Romanowski, E.G., Shanks, R.M.Q., et al. A. CAP37-derived antimicrobial peptides have in vitro antiviral activity against adenovirus and herpes simplex virus type-1. Curr. Eye Res. 34:241-249, 2009.
58. Pereira, H.A., Tsyshevskaya-Hoover, I., Hinsley, H., et al. Candidacidal activity of synthetic peptides based on the antimicrobial domain of the neutrophil-derived protein, CAP37. Med. Mycol. 48:263-272, 2010.
59. Huang, S., Kamata, T., Takada, Y., Ruggeri, Z.M., and Nemerow, G.R. Adenovirus interaction with distinct in-tegrins mediates separate events in cell entry and gene delivery to hematopoietic cells. J. Virol. 70:4502-4508, 1996.
60. Sacramento, R.S., Martins, R.M., Miranda, A., et al. Differential effects of a-helical and b-hairpin antimicrobial peptides against Acanthamoeba castellanii. Parasitology 136:813-821, 2009.
61. Martins, R.M., Sforca, M.L., Amino, R., et al. Lytic activity and structural differences of amphipathic peptides derived from trialysin. Biochemistry. 45:1765-1774, 2006.
62. Silva Jr., P.I., Daffre, S., and Bulet, P. Isolation and characterization of gomesin, an 18-residue cysteine rich defense peptide from the spider Acanthoscurria gomesiana hemo-cytes with sequence similarities to horshoe crab antimicrobial peptides of the tachyplesin family. J. Biol. Chem. 275:33464-33470, 2000.
63. Mandard, N., Bulet, P., Caille, A., Daffre, S., and Vovelle, F. The solution structure of gomesin, an antimicrobial cysteine-rich peptide from the spider. Eur. J. Biochem. 269:1190-1198, 2002.
64. Lee, V.H. Membrane transporters. Eur. J. Pharm. Sci. Suppl 2:S41-S50, 2000.
65. Anand, B.S., Nashed, Y., and Mitra, A.K. Novel dipeptide prodrugs of acyclovir for ocular herpes infections: bior-eversion, antiviral activity, and transport across rabbit cornea. Curr. Eye Res. 26:151-163, 2003.
66. Majumdar, S., Nashed, Y.E., Patel, K., et al. Dipeptide monoester ganciclovir prodrugs for treating HSV-1 induced corneal epithelial and stromal keratitis: in vitro and in vivo evaluations. J. Ocul. Pharmacol. Ther. 21:463-474, 2005.
67. Weller, S., Blum, M.R., Doucette, M., et al. Pharmacoki-netics of the acyclovir pro-drug valaciclovir after escalating single-and multiple-dose administration to normal volunteers. Clin. Pharmacol. Ther. 54:595-605, 1993.
68. Park, P.J., Antoine, T.E., Farooq, A.V., Valyi-Nagi, T., and Shukla, D. An investigative peptide-acyclovir combination to control herpes simplex virus type 1 ocular infection. Invest. Ophthalmol. Vis. Sci. 54:6373-6381, 2011.
69. Ganz, T. Defensins and other antimicrobial peptides: a historical persepective and an update. Comb. Chem. High Throughput Screen. 8:209-217, 2005.
70. Henchey, L.K., Jochim, A.L., and Arora, P.S. Contemporary strategies for the stabilization of peptides in the a-helical conformation. Curr. Opin. Chem. Biol. 12:692-697, 2008.
71. Huang, Y., Huang, J., and Chen, Y. Alpha-helical cationic antimicrobial peptides: Relationships of structure and function. Protein Cell. 2:143-152, 2010.
72. Huang, Y., He, L., Li, G., et al. Role of helicity of a-helical antimicrobial peptides to improve specificity. Protein Cell. 5:631-642, 2014.
73. Wild, C., Greenwell, T., et al. The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure. AIDS Res. Hum. Retro-viruses. 11:323, 1995.